Remicade Biosimilars Market 2018-2026| Effective Supply Chain Management To Boost Demand
Biosimilar refers to biotherapeutic product that is similar in terms of quality, efficacy, and safety to an existing licensed reference therapeutic drug. Biological products are the fastest growing class of therapeutic products, as they offer additional treatment options and help in lowering healthcare costs. Biosimilars are almost identical copies of the originally approved drugs and can be manufactured only when the patent for the original innovator drug expires. These products are highly sensitive to smallest changes in manufacturing procedure, as these drugs possess high molecular complexity. Remicade (Infliximab) refers to a chimeric monoclonal antibody biologic licensed by U.S. FDA in 1998, as an innovative product indicated for the treatment of Crohn’s disease in adults and children. The monoclonal antibody drug was first developed in partnership by Janssen Biotech, Inc. and Merck & Co. The Remicade was later approved for its use in the treatment of ulcerative colitis, plague psoriasis, rheumatic arthritis, and spinal psoriatic arthritis in combination with methotrexate. Later, various pharmaceutical manufacturers developed biosimilars to infliximab, which lowered market share of Remicade due to cost-effective prices.
Regional Insights
On the basis
of region, the global Remicade biosimilar market is segmented into
North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa. Europe holds a dominant position in the global Remicade
biosimilar market and is expected to retain its dominance over the
forecast period, owing to the presence of top market players in the
region, rapid entry of biosimilars in the European market as well as
high adoption rate due low price of the biosimilars. For instance, in
2018, Sandoz, a Novartis division received European Commission (EC)
approval for Zessly (infliximab) a remicade biosimilar for use in
Europe. The successive research and speedy approvals by the U.S.
regulatory authorities for market entry of biosimilars in North
America is expected to drive growth of the market over the forecast
period. For instance, in December 2017, Pfizer, Inc. received the
U.S. FDA approval for second biosimilar, Ifixi to Janssen’s
blockbuster drug Remicade to treat rheumatoid arthritis.
Furthermore,
Asia Pacific is expected to witness significant growth in the market
over the forecast period, owing to developments in healthcare
infrastructure and U.S. FDA approval of Remicade (infliximab)
biosimilars by regional players to market the products
internationally. For instance, in April 2016, Celltrion- a South
Korea-based manufacturing company received the U.S. FDA approval for
intravenously administered version of the rheumatoid arthritis drug
sold under the name Infllectra. Moreover, major investments by
regional players for research and development of biosimilar
production is expected to drive growth of the market in Asia. For
instance, in October 2016, Cipla, Inc. invested US$ 8 million to set
up a manufacturing plant for biosimilars in South Africa.
Competitive Landscape
Key players
operating in the global remicade biosimilar market include Janssen
Biotech, Inc., Merck and Company, Inc., Alvogen, Pfizer, Inc.,
Celltrion, Nippon Kayaku, Napp Pharmaceuticals, and others.
Ask For
Discount Before Purchasing This Business Report @
https://www.coherentmarketinsights.com/insight/request-discount/1769
Market
Taxonomy:
On the
basis of disease indication, the global Remicade biosimilars market
is segmented into:
-
Ulcerative Colitis
-
Rheumatoid Arthritis
-
Ankylosing Spondylitis
-
Crohn’s Disease
-
Psoriatic Arthritis
-
Plaque Psoriasis
On the
basis of geography, the global Remicade biosimilars market is
segmented into:
-
North America
-
Latin America
-
Europe
-
Asia Pacific
-
Middle East
-
Africa
About
Coherent Market Insights
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us
Mr.
Shah
Coherent
Market Insights
1001
4th Ave, #3200
Seattle,
WA 98154
Tel:
+1-206-701-6702

Comments
Post a Comment